TELA BIO INC (TELA) Fundamental Analysis & Valuation

NASDAQ:TELA • US8723811084

Current stock price

0.6 USD
-0.07 (-10.45%)
Last:

This TELA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TELA Profitability Analysis

1.1 Basic Checks

  • TELA had negative earnings in the past year.
  • In the past year TELA has reported a negative cash flow from operations.
  • In the past 5 years TELA always reported negative net income.
  • In the past 5 years TELA always reported negative operating cash flow.
TELA Yearly Net Income VS EBIT VS OCF VS FCFTELA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • TELA has a worse Return On Assets (-47.69%) than 67.02% of its industry peers.
  • With a Return On Equity value of -615.10%, TELA is not doing good in the industry: 84.04% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -47.69%
ROE -615.1%
ROIC N/A
ROA(3y)-50.4%
ROA(5y)-53.94%
ROE(3y)-331.74%
ROE(5y)-294.07%
ROIC(3y)N/A
ROIC(5y)N/A
TELA Yearly ROA, ROE, ROICTELA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400 -600 -800

1.3 Margins

  • TELA's Gross Margin of 67.69% is fine compared to the rest of the industry. TELA outperforms 73.94% of its industry peers.
  • TELA's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TELA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y1.88%
TELA Yearly Profit, Operating, Gross MarginsTELA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TELA Health Analysis

2.1 Basic Checks

  • TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TELA has more shares outstanding than it did 1 year ago.
  • TELA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TELA has a worse debt to assets ratio.
TELA Yearly Shares OutstandingTELA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
TELA Yearly Total Debt VS Total AssetsTELA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • TELA has an Altman-Z score of -6.13. This is a bad value and indicates that TELA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TELA (-6.13) is worse than 73.40% of its industry peers.
  • A Debt/Equity ratio of 8.82 is on the high side and indicates that TELA has dependencies on debt financing.
  • TELA's Debt to Equity ratio of 8.82 is on the low side compared to the rest of the industry. TELA is outperformed by 86.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.82
Debt/FCF N/A
Altman-Z -6.13
ROIC/WACCN/A
WACC11.29%
TELA Yearly LT Debt VS Equity VS FCFTELA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 4.20 indicates that TELA has no problem at all paying its short term obligations.
  • TELA has a better Current ratio (4.20) than 67.02% of its industry peers.
  • A Quick Ratio of 3.59 indicates that TELA has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 3.59, TELA is doing good in the industry, outperforming 69.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 3.59
TELA Yearly Current Assets VS Current LiabilitesTELA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. TELA Growth Analysis

3.1 Past

  • TELA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.01%, which is quite impressive.
  • The Revenue has grown by 15.84% in the past year. This is quite good.
  • TELA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.54% yearly.
EPS 1Y (TTM)41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.43%
Revenue 1Y (TTM)15.84%
Revenue growth 3Y24.68%
Revenue growth 5Y34.54%
Sales Q2Q%18.25%

3.2 Future

  • Based on estimates for the next years, TELA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.27% on average per year.
  • TELA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.26% yearly.
EPS Next Y27.08%
EPS Next 2Y23.04%
EPS Next 3Y24.27%
EPS Next 5YN/A
Revenue Next Year15.2%
Revenue Next 2Y15.82%
Revenue Next 3Y16.26%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TELA Yearly Revenue VS EstimatesTELA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
TELA Yearly EPS VS EstimatesTELA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. TELA Valuation Analysis

4.1 Price/Earnings Ratio

  • TELA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TELA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELA Price Earnings VS Forward Price EarningsTELA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELA Per share dataTELA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TELA's earnings are expected to grow with 24.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.04%
EPS Next 3Y24.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TELA Dividend Analysis

5.1 Amount

  • TELA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TELA Fundamentals: All Metrics, Ratios and Statistics

TELA BIO INC

NASDAQ:TELA (3/30/2026, 3:20:12 PM)

0.6

-0.07 (-10.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-24
Earnings (Next)05-06
Inst Owners72.12%
Inst Owner Change16.55%
Ins Owners9.24%
Ins Owner Change7.28%
Market Cap26.26M
Revenue(TTM)80.28M
Net Income(TTM)-38.83M
Analysts81.82
Price Target3.52 (486.67%)
Short Float %1.59%
Short Ratio3.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.24%
Min EPS beat(2)6.39%
Max EPS beat(2)14.09%
EPS beat(4)2
Avg EPS beat(4)-6.7%
Min EPS beat(4)-25.31%
Max EPS beat(4)14.09%
EPS beat(8)3
Avg EPS beat(8)2.41%
EPS beat(12)5
Avg EPS beat(12)1.25%
EPS beat(16)6
Avg EPS beat(16)-2.24%
Revenue beat(2)0
Avg Revenue beat(2)-4.85%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-2.79%
Revenue beat(4)1
Avg Revenue beat(4)-2.34%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)4.59%
Revenue beat(8)1
Avg Revenue beat(8)-6.36%
Revenue beat(12)2
Avg Revenue beat(12)-5.19%
Revenue beat(16)5
Avg Revenue beat(16)-4.56%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 4.16
P/tB 5.3
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS1.83
BVpS0.14
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.69%
ROE -615.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.69%
FCFM N/A
ROA(3y)-50.4%
ROA(5y)-53.94%
ROE(3y)-331.74%
ROE(5y)-294.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y1.88%
F-Score3
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 8.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.36%
Cap/Sales 0.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 3.59
Altman-Z -6.13
F-Score3
WACC11.29%
ROIC/WACCN/A
Cap/Depr(3y)72.57%
Cap/Depr(5y)99.01%
Cap/Sales(3y)1.01%
Cap/Sales(5y)1.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.43%
EPS Next Y27.08%
EPS Next 2Y23.04%
EPS Next 3Y24.27%
EPS Next 5YN/A
Revenue 1Y (TTM)15.84%
Revenue growth 3Y24.68%
Revenue growth 5Y34.54%
Sales Q2Q%18.25%
Revenue Next Year15.2%
Revenue Next 2Y15.82%
Revenue Next 3Y16.26%
Revenue Next 5YN/A
EBIT growth 1Y19.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.37%
EBIT Next 3Y31.65%
EBIT Next 5YN/A
FCF growth 1Y32.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.16%
OCF growth 3YN/A
OCF growth 5YN/A

TELA BIO INC / TELA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TELA BIO INC?

ChartMill assigns a fundamental rating of 2 / 10 to TELA.


Can you provide the valuation status for TELA BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to TELA BIO INC (TELA). This can be considered as Overvalued.


Can you provide the profitability details for TELA BIO INC?

TELA BIO INC (TELA) has a profitability rating of 1 / 10.


What is the financial health of TELA BIO INC (TELA) stock?

The financial health rating of TELA BIO INC (TELA) is 2 / 10.


What is the earnings growth outlook for TELA BIO INC?

The Earnings per Share (EPS) of TELA BIO INC (TELA) is expected to grow by 27.08% in the next year.